Protocol Ledger

NCT07513285 · Phase II · RECRUITING

ACX-362E [Ibezapolstat] for Oral Treatment of Recurrent Clostridioides Difficile Infection

Interventional Phase II clinical trial protocol NCT07513285 sponsored by Acurx Pharmaceuticals in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-09-25 Enrollment: 20 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07513285
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)20 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07513285
Protocol FieldVerified Registry Value
NCT IdentifierNCT07513285
Consolidated Lead SponsorAcurx Pharmaceuticals
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment20 participants (ESTIMATED)
Registered Start Date2026-09-25
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07513285
Hospital Research SiteLocationSite Profile
UC Davis Comprehensive Cancer CenterSacramento, CAOpen Hospital Dossier ->
Henry Ford HospitalDetroit, MIOpen Hospital Dossier ->
University of MinnesotaMinneapolis, MNOpen Hospital Dossier ->
University of CincinnatiCincinnati, OHOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI